Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 436-439

  Pidaparti, Mahati ^a   Bostrom, Bruce ^a  

^a CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

Author keywords

Allergic reactions; Asparaginase; Intramuscular; Intravenous; Pegasparaginase

Indexed keywords

ASPARAGINASE MACROGOL;

ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALE; POLYETHYLENE GLYCOLS; RISK;

EID: 84862697123     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23380     Document Type: Article

References (13)

1. Rytting M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther 2010; 10: 833-839.
2. Zeidan A, Wang E, Wetzler M. Pegasparaginase: Where do we stand? Expert Opin Biol Ther 2009; 9: 111-119.
3. Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2009; 7: 600-606.
4. Narta U, Kanwar S, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol/Hematol 2007; 61: 208-221.
5. Raetz E, Salzer W. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010; 32: 544-563.
6. Avramis V, Sencer S, Periclou A, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2002; 99: 1986-1994.
7. Silverman L, Gelber R, Dalton V, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211-1218.
8. Woo MJ, Hak LJ, Evans WE, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 1527-1533.
9. Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54: 199-205.
10. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular verses intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979; 1: 9-13.
11. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008; 14: 191-202.
12. Douer D, Yampolsky H, Cohen L, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007; 109: 2744-2750.
13. Silverman L, Supko J, Stevenson K, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010; 115: 1351-1353.